Figure 4.

Western blot for vimentin and α-1-microglobulin/bikunin precursor (AMBP) in adipose tissue from controls (n = 7) and lean chronic kidney disease (CKD) patients (n = 13). β-actin was used as a loading control. Half of the CKD samples and all of the control samples were run on 1 gel and the other half of the CKD samples and the same control samples were run on a second gel (space restrictions prevented the loading of all samples on 1 gel). Blots of the control samples are shown only once for ease of understanding. AMBP is consistently higher in the CKD patients, whereas the lower molecular weight forms of vimentin are generally lower in the CKD patients as compared to the controls (visual assessment).